nodes	percent_of_prediction	percent_of_DWPC	metapath
Tapentadol—Sexual dysfunction—Hydrochlorothiazide—nephrolithiasis	0.0363	0.0614	CcSEcCtD
Tapentadol—Feeling hot—Hydrochlorothiazide—nephrolithiasis	0.0259	0.0439	CcSEcCtD
Tapentadol—Memory impairment—Hydrochlorothiazide—nephrolithiasis	0.0259	0.0439	CcSEcCtD
Tapentadol—Gamma-glutamyltransferase increased—Hydrochlorothiazide—nephrolithiasis	0.0247	0.0419	CcSEcCtD
Tapentadol—CYP2C19—urine—nephrolithiasis	0.022	0.167	CbGeAlD
Tapentadol—Coordination abnormal—Hydrochlorothiazide—nephrolithiasis	0.0207	0.0351	CcSEcCtD
Tapentadol—CYP2C9—urine—nephrolithiasis	0.0171	0.129	CbGeAlD
Tapentadol—Hot flush—Hydrochlorothiazide—nephrolithiasis	0.0158	0.0267	CcSEcCtD
Tapentadol—Menopausal symptoms—Hydrochlorothiazide—nephrolithiasis	0.0156	0.0265	CcSEcCtD
Tapentadol—Visual disturbance—Hydrochlorothiazide—nephrolithiasis	0.0156	0.0264	CcSEcCtD
Tapentadol—HTR3A—Ion channel transport—CLCN5—nephrolithiasis	0.0147	0.0528	CbGpPWpGaD
Tapentadol—HTR3A—Ion channel transport—CLCN4—nephrolithiasis	0.0147	0.0528	CbGpPWpGaD
Tapentadol—UGT1A9—renal system—nephrolithiasis	0.0145	0.11	CbGeAlD
Tapentadol—UGT1A9—kidney—nephrolithiasis	0.014	0.106	CbGeAlD
Tapentadol—Ataxia—Hydrochlorothiazide—nephrolithiasis	0.0139	0.0235	CcSEcCtD
Tapentadol—Breast disorder—Hydrochlorothiazide—nephrolithiasis	0.0133	0.0226	CcSEcCtD
Tapentadol—Aspartate aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.0133	0.0225	CcSEcCtD
Tapentadol—Alanine aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.013	0.022	CcSEcCtD
Tapentadol—CYP2D6—urine—nephrolithiasis	0.0128	0.0969	CbGeAlD
Tapentadol—Upper respiratory tract infection—Hydrochlorothiazide—nephrolithiasis	0.0119	0.0201	CcSEcCtD
Tapentadol—Pollakiuria—Hydrochlorothiazide—nephrolithiasis	0.0118	0.02	CcSEcCtD
Tapentadol—Erectile dysfunction—Hydrochlorothiazide—nephrolithiasis	0.0117	0.0199	CcSEcCtD
Tapentadol—UGT2B7—renal system—nephrolithiasis	0.0117	0.0885	CbGeAlD
Tapentadol—OPRD1—renal system—nephrolithiasis	0.0115	0.0867	CbGeAlD
Tapentadol—UGT2B7—kidney—nephrolithiasis	0.0113	0.0855	CbGeAlD
Tapentadol—OPRD1—kidney—nephrolithiasis	0.0111	0.0839	CbGeAlD
Tapentadol—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.0111	0.0187	CcSEcCtD
Tapentadol—Bradycardia—Hydrochlorothiazide—nephrolithiasis	0.0104	0.0176	CcSEcCtD
Tapentadol—Hypoaesthesia—Hydrochlorothiazide—nephrolithiasis	0.0102	0.0172	CcSEcCtD
Tapentadol—Visual impairment—Hydrochlorothiazide—nephrolithiasis	0.00984	0.0167	CcSEcCtD
Tapentadol—Tension—Hydrochlorothiazide—nephrolithiasis	0.00872	0.0148	CcSEcCtD
Tapentadol—UGT2B7—Phase II conjugation—SLC26A1—nephrolithiasis	0.0087	0.0314	CbGpPWpGaD
Tapentadol—Nervousness—Hydrochlorothiazide—nephrolithiasis	0.00863	0.0146	CcSEcCtD
Tapentadol—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.00837	0.0142	CcSEcCtD
Tapentadol—Tremor—Hydrochlorothiazide—nephrolithiasis	0.00833	0.0141	CcSEcCtD
Tapentadol—Agitation—Hydrochlorothiazide—nephrolithiasis	0.00817	0.0138	CcSEcCtD
Tapentadol—Angioedema—Hydrochlorothiazide—nephrolithiasis	0.00812	0.0138	CcSEcCtD
Tapentadol—Vertigo—Hydrochlorothiazide—nephrolithiasis	0.00798	0.0135	CcSEcCtD
Tapentadol—Syncope—Hydrochlorothiazide—nephrolithiasis	0.00797	0.0135	CcSEcCtD
Tapentadol—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.00785	0.0133	CcSEcCtD
Tapentadol—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.00781	0.0132	CcSEcCtD
Tapentadol—Cough—Hydrochlorothiazide—nephrolithiasis	0.00775	0.0131	CcSEcCtD
Tapentadol—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.00756	0.0128	CcSEcCtD
Tapentadol—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.00754	0.0128	CcSEcCtD
Tapentadol—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.0074	0.0125	CcSEcCtD
Tapentadol—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.00733	0.0264	CbGpPWpGaD
Tapentadol—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.00731	0.0124	CcSEcCtD
Tapentadol—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.00725	0.0123	CcSEcCtD
Tapentadol—Oedema—Hydrochlorothiazide—nephrolithiasis	0.00725	0.0123	CcSEcCtD
Tapentadol—Shock—Hydrochlorothiazide—nephrolithiasis	0.00713	0.0121	CcSEcCtD
Tapentadol—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00708	0.012	CcSEcCtD
Tapentadol—UGT1A9—Phase II conjugation—SLC26A1—nephrolithiasis	0.00707	0.0255	CbGpPWpGaD
Tapentadol—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.00701	0.0119	CcSEcCtD
Tapentadol—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.00681	0.0246	CbGpPWpGaD
Tapentadol—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.00678	0.0115	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.00661	0.0112	CcSEcCtD
Tapentadol—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.00656	0.0111	CcSEcCtD
Tapentadol—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.00651	0.011	CcSEcCtD
Tapentadol—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.00647	0.011	CcSEcCtD
Tapentadol—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.00645	0.0109	CcSEcCtD
Tapentadol—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00638	0.0108	CcSEcCtD
Tapentadol—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.0063	0.0107	CcSEcCtD
Tapentadol—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.00625	0.0106	CcSEcCtD
Tapentadol—Constipation—Hydrochlorothiazide—nephrolithiasis	0.0062	0.0105	CcSEcCtD
Tapentadol—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.00598	0.0101	CcSEcCtD
Tapentadol—UGT2B7—NRF2 pathway—SLC2A9—nephrolithiasis	0.0058	0.0209	CbGpPWpGaD
Tapentadol—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.00576	0.00976	CcSEcCtD
Tapentadol—SLC6A4—NRF2 pathway—SLC2A9—nephrolithiasis	0.00571	0.0206	CbGpPWpGaD
Tapentadol—OPRD1—G alpha (i) signalling events—RGS14—nephrolithiasis	0.00561	0.0202	CbGpPWpGaD
Tapentadol—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.00534	0.00905	CcSEcCtD
Tapentadol—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.0052	0.00881	CcSEcCtD
Tapentadol—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.00513	0.00869	CcSEcCtD
Tapentadol—HTR3A—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.0051	0.0184	CbGpPWpGaD
Tapentadol—HTR3A—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.0051	0.0184	CbGpPWpGaD
Tapentadol—UGT2B7—Biological oxidations—SLC26A1—nephrolithiasis	0.00509	0.0183	CbGpPWpGaD
Tapentadol—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.00496	0.00841	CcSEcCtD
Tapentadol—OPRK1—G alpha (i) signalling events—RGS14—nephrolithiasis	0.00492	0.0177	CbGpPWpGaD
Tapentadol—SLC6A2—NRF2 pathway—SLC2A9—nephrolithiasis	0.00491	0.0177	CbGpPWpGaD
Tapentadol—SLC6A2—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.0048	0.0173	CbGpPWpGaD
Tapentadol—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.0048	0.00812	CcSEcCtD
Tapentadol—UGT1A9—NRF2 pathway—SLC2A9—nephrolithiasis	0.00471	0.017	CbGpPWpGaD
Tapentadol—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00461	0.00781	CcSEcCtD
Tapentadol—Rash—Hydrochlorothiazide—nephrolithiasis	0.00457	0.00775	CcSEcCtD
Tapentadol—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.00457	0.00774	CcSEcCtD
Tapentadol—HTR3A—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00455	0.0164	CbGpPWpGaD
Tapentadol—Headache—Hydrochlorothiazide—nephrolithiasis	0.00454	0.0077	CcSEcCtD
Tapentadol—SLC6A2—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00439	0.0158	CbGpPWpGaD
Tapentadol—SLC6A2—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00439	0.0158	CbGpPWpGaD
Tapentadol—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00431	0.0073	CcSEcCtD
Tapentadol—HTR3A—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00416	0.015	CbGpPWpGaD
Tapentadol—HTR3A—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00416	0.015	CbGpPWpGaD
Tapentadol—OPRM1—G alpha (i) signalling events—RGS14—nephrolithiasis	0.00416	0.015	CbGpPWpGaD
Tapentadol—UGT1A9—Biological oxidations—SLC26A1—nephrolithiasis	0.00414	0.0149	CbGpPWpGaD
Tapentadol—SLC6A2—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00333	0.012	CbGpPWpGaD
Tapentadol—SLC6A2—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00333	0.012	CbGpPWpGaD
Tapentadol—HTR3A—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00315	0.0114	CbGpPWpGaD
Tapentadol—HTR3A—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00315	0.0114	CbGpPWpGaD
Tapentadol—CYP2D6—renal system—nephrolithiasis	0.00314	0.0237	CbGeAlD
Tapentadol—SLC6A2—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.0031	0.0112	CbGpPWpGaD
Tapentadol—SLC6A2—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.0031	0.0112	CbGpPWpGaD
Tapentadol—CYP2D6—kidney—nephrolithiasis	0.00303	0.0229	CbGeAlD
Tapentadol—HTR3A—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00293	0.0106	CbGpPWpGaD
Tapentadol—HTR3A—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00293	0.0106	CbGpPWpGaD
Tapentadol—SLC6A2—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00276	0.00994	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00274	0.00987	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00274	0.00987	CbGpPWpGaD
Tapentadol—HTR3A—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00261	0.00942	CbGpPWpGaD
Tapentadol—HTR3A—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00261	0.00942	CbGpPWpGaD
Tapentadol—OPRD1—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00254	0.00916	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00244	0.0088	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00223	0.00805	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00223	0.00805	CbGpPWpGaD
Tapentadol—OPRK1—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00223	0.00803	CbGpPWpGaD
Tapentadol—OPRD1—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00218	0.00785	CbGpPWpGaD
Tapentadol—HTR3A—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.00209	0.00753	CbGpPWpGaD
Tapentadol—CYP2C19—Biological oxidations—SLC26A1—nephrolithiasis	0.00194	0.00701	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—RGS14—nephrolithiasis	0.00192	0.00692	CbGpPWpGaD
Tapentadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00191	0.00688	CbGpPWpGaD
Tapentadol—OPRM1—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00188	0.00679	CbGpPWpGaD
Tapentadol—CYP2D6—Biological oxidations—SLC26A1—nephrolithiasis	0.00179	0.00644	CbGpPWpGaD
Tapentadol—CYP2C9—Biological oxidations—SLC26A1—nephrolithiasis	0.00177	0.00639	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—RGS14—nephrolithiasis	0.00174	0.00628	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00169	0.0061	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00169	0.0061	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—RGS14—nephrolithiasis	0.00168	0.00607	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—CHRM3—nephrolithiasis	0.00166	0.00598	CbGpPWpGaD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00161	0.00582	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00157	0.00567	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00157	0.00567	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—RGS14—nephrolithiasis	0.00153	0.00551	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—PTH—nephrolithiasis	0.00152	0.00547	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—CHRM3—nephrolithiasis	0.00145	0.00524	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—RGS14—nephrolithiasis	0.00142	0.00513	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.0014	0.00505	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.0014	0.00505	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—PTH—nephrolithiasis	0.00133	0.00479	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—DGKH—nephrolithiasis	0.0013	0.00467	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—RGS14—nephrolithiasis	0.00129	0.00466	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—CHRM3—nephrolithiasis	0.00123	0.00443	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—ADCY10—nephrolithiasis	0.00121	0.00436	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—DGKH—nephrolithiasis	0.00118	0.00424	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—GRHPR—nephrolithiasis	0.00115	0.00414	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—DGKH—nephrolithiasis	0.00114	0.0041	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—PTH—nephrolithiasis	0.00112	0.00405	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.00112	0.00404	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—ADCY10—nephrolithiasis	0.00106	0.00383	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—DGKH—nephrolithiasis	0.00103	0.00372	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—RGS14—nephrolithiasis	0.00103	0.00371	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—AGXT—nephrolithiasis	0.00102	0.00369	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—DGKH—nephrolithiasis	0.000961	0.00346	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000937	0.00338	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—GRHPR—nephrolithiasis	0.000933	0.00336	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—RGS14—nephrolithiasis	0.000903	0.00325	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—ADCY10—nephrolithiasis	0.000897	0.00323	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—DGKH—nephrolithiasis	0.000872	0.00314	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—APRT—nephrolithiasis	0.00087	0.00314	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—SLC26A1—nephrolithiasis	0.00087	0.00314	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—PTH—nephrolithiasis	0.000857	0.00309	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—CHRM3—nephrolithiasis	0.000851	0.00307	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—AGXT—nephrolithiasis	0.000832	0.003	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000822	0.00296	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—PTH—nephrolithiasis	0.000778	0.00281	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—RGS14—nephrolithiasis	0.000763	0.00275	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—PTH—nephrolithiasis	0.000752	0.00271	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—CHRM3—nephrolithiasis	0.000746	0.00269	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—SLC26A1—nephrolithiasis	0.000707	0.00255	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—APRT—nephrolithiasis	0.000707	0.00255	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—DGKH—nephrolithiasis	0.000695	0.00251	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000695	0.00251	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000695	0.0025	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—PTH—nephrolithiasis	0.000683	0.00246	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—PTH—nephrolithiasis	0.000635	0.00229	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—CHRM3—nephrolithiasis	0.000631	0.00227	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—AQP1—nephrolithiasis	0.00062	0.00224	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00061	0.0022	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—DGKH—nephrolithiasis	0.00061	0.0022	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—PTH—nephrolithiasis	0.000577	0.00208	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—CHRM3—nephrolithiasis	0.000561	0.00202	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000515	0.00186	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—DGKH—nephrolithiasis	0.000515	0.00186	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—AQP1—nephrolithiasis	0.000504	0.00182	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CHRM3—nephrolithiasis	0.000503	0.00181	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PTH—nephrolithiasis	0.00046	0.00166	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—CHRM3—nephrolithiasis	0.000456	0.00164	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CHRM3—nephrolithiasis	0.000441	0.00159	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GRHPR—nephrolithiasis	0.000439	0.00158	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GRHPR—nephrolithiasis	0.000403	0.00145	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PTH—nephrolithiasis	0.000403	0.00145	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GRHPR—nephrolithiasis	0.0004	0.00144	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—AGXT—nephrolithiasis	0.000391	0.00141	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CHRM3—nephrolithiasis	0.000373	0.00134	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—AGXT—nephrolithiasis	0.00036	0.0013	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—AGXT—nephrolithiasis	0.000356	0.00128	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PTH—nephrolithiasis	0.000341	0.00123	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—APRT—nephrolithiasis	0.000332	0.0012	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—SLC26A1—nephrolithiasis	0.000332	0.0012	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—APRT—nephrolithiasis	0.000306	0.0011	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—SLC26A1—nephrolithiasis	0.000306	0.0011	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—APRT—nephrolithiasis	0.000303	0.00109	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—SLC26A1—nephrolithiasis	0.000303	0.00109	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—AQP1—nephrolithiasis	0.000237	0.000854	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—SPP1—nephrolithiasis	0.000231	0.000832	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—AQP1—nephrolithiasis	0.000218	0.000785	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—AQP1—nephrolithiasis	0.000216	0.000778	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CHRM3—nephrolithiasis	0.000214	0.000772	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—SPP1—nephrolithiasis	0.000202	0.00073	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CHRM3—nephrolithiasis	0.000197	0.00071	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CHRM3—nephrolithiasis	0.000195	0.000704	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—SPP1—nephrolithiasis	0.000171	0.000617	CbGpPWpGaD
